However, our data are correlative and do not establish direct causality, recent clinical studies have shown that enhancing regulatory T-cell responses with recombinant human GM-CSF (sargramostim; NCT03790670) can modulate peripheral immune activity and may exert neuroprotective effects in PD [60,61]. The gene discussed is CSF2; the disease is Parkinson disease.